Apogee Therapeutics Inc

APGE remains in a Stage 2 advancing uptrend characterized by a steep parabolic acceleration. Price is currently pulling back into the rising 9/21 EMA confluence after an extended run. Despite overbought RSI and elevated Options Score, our momentum-oriented strategy supports buying shallow pullbacks into EMAs. We advise a Buy Now posture on this retracement, acknowledging the risk of a Stage 3 transition and potential deeper correction if EMAs fail.

• ↑AbbVie to acquire at $135.11, 53% premium secures direct cash return.
• ↑247% 1-year gain to $133.88 52-week high highlights strong momentum.
• ↓Negative earnings yield and poor profitability underscore weak margins.